GovChime
Notice ID: f1e06bcdb7e14b14ac9eba218f8b057bPresolicitation

ABI Scientific Branded Cell Growth Enhancers & Cell Mediums

Archived. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−04:00
Posted
May 17, 2023
Notice type
Presolicitation
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Rockville, MD, 20852
Last updated
Dec 4, 2025

Identifiers

Solicitation number
NOI-NIAID-23-2174676
Notice ID
f1e06bcdb7e14b14ac9eba218f8b057b

Description

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with ABI Scientific Inc., 150 S Sterling Blvd #84, Sterling , VA 201064. The National Institute of Allergy and Infectious Diseases (NIAID) s Vaccine Research Center (VRC) (collectively Program ) is developing vaccines for HIV-1 and SARS-CoV-2 and other viruses. Production of various wild-type and mutant viral proteins and anti-viral antibodies is critical in vaccine development. These viral proteins and antibodies need to be expressed in cell lines. The proteins will be used in crystallography for structural analysis, immunogen screening and pre-clinical animal studies. In order to create cells to create these proteins, cell growth enhancers and cell mediums are needed. Program has technical and compatibility requirements to use this specific ABI Scientific Inc. brand and model of cell growth and cell medium items. Program requires specific types of high quality and carefully controlled growth mediums, cell expression mediums, etc., to conduct its research. ABI Cell Medium, Adherent Cell Expression Medium and CelBooster, Cell Growth Enhancer for adherent cells are used to enhance the protein yield and quality through enhancement of cell growth metabolism pathways and leading to dramatically increasing the efficiency of gene transcription, protein translation and after-translation modification within the cells. Program has undertaken extensive testing of these mediums, and any changes in source will be disruptive to a number of operating protocols within the Vaccine Research Center. Changing to different mediums/different products may also introduce new variables that may cause future data to be incomparable with previous data and may jeopardize research. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following: 1. Part #: PB2462; Description: CelBooster, Cell Growth Enhancer for adherent cells, 250mL x 30-Qty 2. Part #: CM6600; Description: ABI Cell Medium, 250mL x 120-Qty 3. Part #: TM9000; Description: Adherent Cell Expression Medium, 250mL x 60-Qty 4. Shipping & Handling shall be included in the price. Place of Performance or Delivery: Delivery within four (4) weeks after receipt of order at Bethesda, MD 20892. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2174676) by 4:00 pm eastern standard time on May 24, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:NOI-NIAID-23-2174676
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentMay 17, 2023

    ABI Scientific Branded Cell Growth Enhancers & Cell Mediums

    Notice f1e06bcdb7e14b14ac9eba218f8b057b on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
71%
Combined Synopsis11/04/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
66%
Pre-Solicitation11/11/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited. The National Institutes of Health (NIH) Clinical Center (CC) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. This includes the purchase of Gammagard S/D 10gm and Gammagard S/D 5gm kits. The NIH CC Pharmacy is requesting the purchase of 10 bottles each of Gammagard S/D 10gm and Gammagard S/D 5gm kits and as needed to provide anticipated current patient care need. Justification: TAKEDA Group is the only responsible source for Gammagard S/D. There are multiple patients in the NIH currently on therapy with Gammagard S/D and additional patients may be transferred to the NIH for evaluation and treatment. Gammagard S/D is on the Clinical Center’s formulary, requiring a supply to be available in the Pharmacy Department at all times to support ongoing patient care. The NIH needs to keep using the same items to keep treatment consistent.
59%
Pre-Solicitation11/16/2026
Egg-Free Influenza Vaccine Solicitation: SPE2DP26R0004
57%
Solicitation12/03/2026
Influenza Vaccine Solicitation: SPE2DP26R0003
57%
Solicitation12/03/2026

Additional Details

Solicitation Number

NOI-NIAID-23-2174676

Archive Date

Not specified

Office Address

BETHESDA, MD, 20892